Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

ICU TopicsCardiovascular

ICU · Cardiovascular

Acute myocarditis and pericarditis

Also known as Acute myocarditis · Fulminant myocarditis · Giant cell myocarditis · Eosinophilic myocarditis

Acute myocarditis is inflammation of the myocardium — commonest causes: viral (coxsackie, parvovirus B19, COVID-19), autoimmune, drug-induced (immune checkpoint inhibitors), idiopathic. Presents with: chest pain (may mimic MI), heart failure, arrhythmia, or cardiogenic shock (fulminant myocarditis). Diagnosis: troponin elevated, ECG changes (non-specific ST/T changes, may mimic MI), echo (regional wall motion abnormalities, reduced EF), cardiac MRI (gold non-invasive — oedema, late gadolinium enhancement in subepicardial/mid-wall pattern), endomyocardial biopsy (gold standard but rarely performed). Treatment: supportive (heart failure therapy, mechanical support if fulminant), avoid NSAIDs in acute phase (may worsen inflammation). Giant cell myocarditis: urgent immunosuppression + transplant evaluation.

medium16 referencesUpdated 20 Aug 202614 min readVerification in progress

Practise this topic

  • 10 MCQs

Your progress

Saved on this device.

Practise this topic10 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Fulminant myocarditis = cardiogenic shock in young otherwise healthy patient — mechanical support (VA-ECMO) may bridge to recovery
  • Giant cell myocarditis: rapidly progressive, fatal without immunosuppression/transplant — urgent biopsy if suspected
  • Immune checkpoint inhibitors (pembarolizumab, nivolumab) can cause fatal myocarditis — stop drug, high-dose steroids
  • Young patient with MI-like presentation but normal coronaries on angiography = suspect myocarditis
On this page
Study tools

Your progress

Saved on this device.

Practise this topic10 MCQs with explanations

Target exams

CICMFFICMEDIC

Red flags

  • Fulminant myocarditis = cardiogenic shock in young otherwise healthy patient — mechanical support (VA-ECMO) may bridge to recovery
  • Giant cell myocarditis: rapidly progressive, fatal without immunosuppression/transplant — urgent biopsy if suspected
  • Immune checkpoint inhibitors (pembarolizumab, nivolumab) can cause fatal myocarditis — stop drug, high-dose steroids
  • Young patient with MI-like presentation but normal coronaries on angiography = suspect myocarditis
The one-line answer

Acute myocarditis is inflammation of the myocardium — most often viral (coxsackie, parvovirus B19, SARS-CoV-2), but also autoimmune, drug-induced, and two killers that hide in the same syndrome: giant cell and immune checkpoint inhibitor myocarditis. Exclude the MI first (normal coronaries on angiography), confirm the diagnosis on cardiac MRI with the updated Lake Louise criteria — the late gadolinium enhancement sits subepicardial or mid-wall, never subendocardial like an infarct. Support the pump, avoid NSAIDs, bridge fulminant shock with mechanical support, and immunosuppress only the right histology — giant cell, eosinophilic, sarcoid, ICI — never viral lymphocytic.[1][2]

Meet the patient

A 28-year-old previously well man, four days after a flu-like illness, arrives breathless, clutching his chest, and presyncopal. He is cool and clammy. HR 128 in sinus tachycardia, BP 78/50, JVP up, bilateral crackles, lactate 4.2. The bedside echo shows a small, thick, poorly contracting LV (ejection fraction around 20 per cent) with a normal-sized RV and a small pericardial effusion. Coronary angiography shows normal epicardial vessels. The troponin is 8,200 ng/L.[3][11]

The registrar reaches for the thrombolysis. Stop. The coronaries are clear, the patient is young, the LV is small and thick rather than dilated — this is fulminant myocarditis, and the next move is mechanical support, not a lytic. Hold that picture and the whole topic slots into place.[3][11]

ICU Fellowship (CICM) Pro

Continue reading

You have read the opening of this topic. The complete unit — every section and its primary-source references — is part of the ICU Fellowship (CICM) fellowship library.

Sign in to continueSee pricing
References16ShowHide
  1. [1]Caforio AL, Pankuweit S, Arbustini E, et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases Eur Heart J, 2013.PMID 23824828
  2. [2]Ammirati E, Bizzi E, Veronese G, et al. Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis Front Med (Lausanne), 2022.PMID 35350578
  3. [3]McCarthy RE 3rd, Boehmer JP, Hruban RH, et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis N Engl J Med, 2000.PMID 10706898
  4. [4]Ferreira VM, Schulz-Menger J, Holmvang G, et al. Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation: Expert Recommendations J Am Coll Cardiol, 2018.PMID 30545455
  5. [5]Friedrich MG, Sechtem U, Schulz-Menger J, et al. Cardiovascular magnetic resonance in myocarditis: A JACC White Paper J Am Coll Cardiol, 2009.PMID 19389557
  6. [6]Cooper LT Jr, Berry GJ, Shabetai R, et al. Idiopathic giant-cell myocarditis--natural history and treatment. Multicenter Giant Cell Myocarditis Study Group Investigators N Engl J Med, 1997.PMID 9197214
  7. [7]Mahmood SS, Fradley MG, Cohen JV, et al. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors J Am Coll Cardiol, 2018.PMID 29567210
  8. [8]Witberg G, Barda N, Hoss S, et al. Myocarditis after Covid-19 Vaccination in a Large Health Care Organization N Engl J Med, 2021.PMID 34614329
  9. [9]Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel N Engl J Med, 2021.PMID 34614328
  10. [10]Brambatti M, Matassini MV, Adler ED, et al. Eosinophilic Myocarditis: Characteristics, Treatment, and Outcomes J Am Coll Cardiol, 2017.PMID 29096807
  11. [11]Veronese G, Ammirati E, Cipriani M, et al. Fulminant myocarditis: Characteristics, treatment, and outcomes Anatol J Cardiol, 2018.PMID 29537977
  12. [12]Aretz HT Myocarditis: the Dallas criteria Hum Pathol, 1987.PMID 3297992
  13. [13]Awadalla M, Golden DLA, Mahmood SS, et al. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors J Immunother Cancer, 2019.PMID 30795818
  14. [14]Khan AA, Ashraf A, Baker D, et al. Clozapine and incidence of myocarditis and sudden death - Long term Australian experience Int J Cardiol, 2017.PMID 28343762
  15. [15]Furlepa M, Watts I, Carr AS Management of Triple M Syndrome: A Narrative Review of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis, Myositis and Myocarditis Cancers (Basel), 2025.PMID 40647363
  16. [16]Segev A, Iqbal E, McDonagh TA, et al. Clozapine-induced myocarditis: electronic health register analysis of incidence, timing, clinical markers and diagnostic accuracy Br J Psychiatry, 2021.PMID 35048875

Test yourself

Practise what you just read

  • 10 MCQs
ICU Fellowship (CICM) Pro

$29/ monthor $279 / year

The complete ICU Fellowship (CICM) library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousAcute Infective Endocarditis — Comprehensive ICU ManagementcardiovascularNextAcute pericarditisCardiovascular